Alpenglow Biosciences Introduces Summit AI for Quantitative Analysis of Whole Tissue Imaging in Dermatology

New multimodal AI platform is designed to turn complex tissue imaging into structured spatial readouts linked to full sample context

SEATTLE--(BUSINESS WIRE)--Alpenglow Biosciences today announced Summit AI, its multimodal AI platform designed to analyze whole tissue volumes and convert complex imaging data into quantitative spatial readouts that remain linked to the original image context.

Built to work with 3D tissue imaging alongside complementary 2D tissue readouts and sample-linked metadata, Summit AI is designed to help teams interpret tissue architecture, cell relationships, and disease states. The platform is initially focused on inflammatory skin disease, where full biopsy context is critical for understanding tissue organization and generating more comparable biological measurements.

Summit AI is powered by an AI foundation model incorporating thousands of human tissue samples generated through Alpenglow’s 3D imaging platform. This foundation enables consistent, scalable analysis across full tissue volumes while preserving the spatial and biological context required for meaningful interpretation.

“Summit AI reflects an important step in how tissue analysis needs to evolve,” said Nicholas Reder, MD, MPH, CEO, Founder & Co-Inventor of Alpenglow Biosciences. “Researchers and drug development teams need more than isolated readouts or fragmented workflows. They need a way to move from image review to quantitative interpretation across the full sample, while preserving the biological context that matters.”

Summit AI is designed to support full-sample analysis, rapid iteration, and a more unified workflow from image review through measurement. The platform also includes built-in uncertainty metrics intended to help teams evaluate confidence in model outputs, identify regions requiring review, and prioritize high-confidence signals for downstream analysis.

The platform’s quantitative outputs are built for biological interpretation and include spatial representations of tissue organization across the full sample, integrated tissue and disease signatures, feature-level measurements, and cohort-level comparisons. In dermatology, this approach is intended to support analysis of structural remodeling, immune organization, and neuroimmune relationships across intact tissue, areas where conventional 2D sections can miss important spatial patterns.

Summit AI builds on Alpenglow’s broader platform for AI-enabled 3D tissue imaging and digital pathology, which digitizes intact tissue samples to generate quantitative 3D datasets while preserving tissue for downstream molecular analysis. Together, these capabilities are designed to support translational research, biomarker development, and decision-making in drug development.

About Alpenglow Biosciences

Alpenglow Biosciences accelerates drug development and improves clinical diagnostics through AI-enabled 3D tissue imaging and digital pathology. The Aurora™ 3D spatial biology platform digitizes intact tissue samples, delivering quantitative 3D datasets while preserving tissue for molecular analysis. By combining high-throughput 3D imaging, data management, and AI-powered analysis, Alpenglow helps researchers uncover biology that conventional 2D methods can miss.